Concentration-dependent collateral sensitivity of cisplatin-resistant gastric cancer cell sublines.
The cisplatin-resistant gastric cancer cell sublines, SNU-601/Cis2 and /Cis10, were 49 and >530 times more resistant to cisplatin, respectively, compared with the drug-sensitive cells, SNU-601/WT. The SNU-601/Cis2 showed cross-resistance to carboplatin, heptaplatin, doxorubicin, mitomycin C, and 5-fluorouracil compared with the SNU-601/WT whereas the SNU-601/Cis10 displayed collateral sensitivity to these drugs with the exception of cisplatin compared with the SNU-601/Cis2, suggesting that the cross-resistance and collateral sensitivity of cisplatin-resistant gastric cancer cells are dependent upon cisplatin concentrations. Altered expression of the antioxidant and transporter genes (metallothionein, catalase, superoxide dismutases, P-glycoprotein, and the breast cancer resistance protein) was involved in these phenotypes of the cisplatin-resistant gastric cancer cell lines.
Xu
Haidong
H
Research Center for Resistant Cells, Chosun University, Gwangju 501-759, Republic of Korea.
Choi
Seok-Min
SM
An
Chun-San
CS
Min
Young-Don
YD
Kim
Kweon-Cheon
KC
Kim
Kyung-Jong
KJ
Choi
Cheol-Hee
CH
D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects*; D002945:Cisplatin / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006801:Humans; D007928:Lethal Dose 50; D009363:Neoplasm Proteins / Q000378:metabolism*; D012680:Sensitivity and Specificity; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology
D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D002945:Cisplatin